Teiko-powered spectral flow reveals dose-dependent immune dynamics in Obsidian's TIL trial

Presented by Hari Parameswaran, CMO at Obsidian Therapeutics, at the SITC Spring Scientific Conference 2026, spectral flow cytometry provided by Teiko was central to characterizing the peripheral immune response across dose levels (DL1, DL2, and DL3/RP2D) in the Phase 1/2 Agni-01 melanoma trial of OBX-115.